

Please type a plus sign (+) inside this box ☐


+

PTO/SB/21 (6-99)

Approved for use through 09/30/2000. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/990,436
Filing Date	November 14, 2001
First Named Inventor	Goddard et al.
Group/Art Unit	1646
Examiner Name	Kemmerer, Elizabeth

Total Number of Pages in This Submission

19 pgs.

Attorney Docket Number

39780-2730P1C14

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> Amendment Under 1.48(b) <input type="checkbox"/> Version with Markings Showing Changes <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): copies of 2 references and a stamped return postcard
Remarks AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER (Reference Atty. Docket No. 39780-2730P1C14).		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual name	GINGER R. DREGER, ESQ., REG. NO. 33,055, HELLER EHRMAN WHITE & McAULIFFE LLP		
Signature			
Date	FEBRUARY 3, 2005	Customer Number:	35489

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Express Mail Label EV 582 629 482 US

Typed or printed name	Sandra Puljic		
Signature		Date	February 3, 2005



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Audrey GODDARD et al. Docket No.: 39780-2730P1C14
Serial No.: 09/990,436 Group Art Unit: 1646
Filing Date: November 14, 2001 Examiner: Elizabeth Kemmerer
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**
EXPRESS MAIL LABEL NO.: EV 582 629 482 US
DATE MAILED: February 3, 2005

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97

MS: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication, except U.S. patents and patent application publications (1276 OG 55), is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §§ 1.97-1.98.

Each reference listed and denoted by an asterisk (*) has been cited in a related patent application, US Serial No. 09/992,643 (claiming PRO 1112 polypeptide); Our Ref. No. 39780-2730 P1C13 and/or US Serial No. 09/989,328 (claiming PRO 1112 nucleic acid); Our Ref. No. 39780-2730 P1C54. A copy of each reference is provided herewith. Applicants submit these documents to ensure that all references are of record and considered in all related applications.

Applicants respectfully request the Examiner to acknowledge consideration of the currently submitted references by initialing and returning form PTO-1449 in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --

02/11/2005 DTESSEM1 00000161 081641 09990436

01 FC:1806 180.00 DA

☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

☐ a certification as specified in §1.97(e) is provided below; or

☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☒ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; and


B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and

C. a fee of \$180.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39780-2730P1C14).

Respectfully submitted,

Dated: February 3, 2005

By: 
Ginger R. Dreger
Reg. No. 43,626

HELLER EHRMAN WHITE & MCAULIFFE, LLP
Customer No. 35489/09157
275 Middlefield Road
Menlo Park, CA 94025-3506
Telephone: (650) 324-7000 /Facsimile: (650) 324-0638



INFORMATION DISCLOSURE STATEMENT PTO-1449		ATTY. DOCKET NO.: 39780-2730P1C14		SERIAL NO.: 09/990,436			
		APPLICANT : Audrey GODDARD et al.					
		FILING DATE: 11/14/2001		GROUP: 1646			
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	* Hu et al., "Analysis of Genomic and Proteomic Data Using Advanced Literature Mining", Journal of Proteome Research, Vol. 2, pp 405-412, 2003.						
	* Laqueyrie et al., "Cloning, Sequencing and Expression of the <i>apa</i> Gene Coding for the <i>Mycobacterium tuberculosis</i> 45/47-Kilodalton Secreted Antigen Complex, Infection and Immunity, Vol. 63, No. 10, pp 4003-4010, October 1995.						
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.